Intellectual Property - November 28, 2018
Special report: The CRISPR/Cas 9 patent battle
In 2012 two scientists, Jennifer Doudna at the University of California, Berkeley, and Emmanuelle Charpentier at the University of Vienna and the University of Umeå, published their ground-breaking findings about the mechanisms behind the CRISPR/Cas 9 system. Text by Pia Andrea Although Jennifer Doudna and Emmanuelle Charpentier were the first to discover, and also the […]
Intellectual Property - November 23, 2018
Moberg Pharma granted patent in China
The company’s MOB-015 has been granted patent protection in China, valid until 2032. MOB-015 is an internally developed topical formulation of terbinafine for the treatment of onychomycosis, currently under clinical development in phase 3. MOB-015’s patent protection thus covers the key markets for commercialization. Moberg Pharma has previously been granted patent protection for MOB-015 in […]
Intellectual Property - November 13, 2018
Follicum expands patent portfolio
The company has submitted a new patent application for its diabetes project and reports promising experimental data. Follicum has identified a new class of peptides that increase insulin secretion in several experimental models. Experimental studies show that the company’s new peptides exert a protective and preservative effect on beta cells exposed to high glucose concentrations […]
Intellectual Property - September 25, 2018
Patent approval for Cantargia in Japan
The Japanese patent authority, JPO has formally approved the company’s patent application of the antibody CAN04 (nidanilimab). CAN04 binds interleukin 1 receptor accessory protein (IL1RAP), blocks its activity and the antibody is being developed for cancer therapy. The granted patent has number JP6396488. The main project, the immuno-oncology antibody CAN04, with a dual mechanism of […]
Intellectual Property - September 19, 2018
LIDDS receives patent protection until 2037
The European Patent Office has approved a novel patent for LIDDS NanoZolid technology. The company’s patent protection for the drug delivery technology is now extended for at least another nineteen years. The new patent protects fundamental aspects of the production process of NanoZolid drug delivery formulations. The patent covers all NanoZolid formulations that are in […]
Intellectual Property - September 12, 2018
Orexo wins appeal against Actavis on Zubsolv patent in the US
The US Court of Appeals for the Federal Circuit found Orexo’s long term Zubsolv patent US 8,940,330 to be valid, and reversed the invalidity decision previously rendered by the District Court of Delaware in November 2016. The decision was rendered in the patent litigation alleging that Actavis’s generic Zubsolv 1.4/0.36 mg and 5.7/1.4 mg buprenorphine/naloxone […]
